News Story: Full Text
Sponsored By
Cleveland Clinic Brain Tumor and Neuro-Oncology Center
Please Click On The Above Banner For More Details
Braintumor Website


TransMolecular Successfully Completes Phase I/II Clinical Trial With its Targeted Oncology Therapeutic


Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)



Website: http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=109&STORY=/www/story/12-07-2004/0002587576&EDATE=

Posted on: 12/07/2004

TransMolecular Successfully Completes Phase I/II Clinical Trial With its Targeted Oncology Therapeutic


BIRMINGHAM, Ala., Dec. 7 /PRNewswire/ -- TransMolecular, Inc. today announced that based on the favorable initial safety and tolerability profile of its anti-cancer therapeutic, 131I-TM-601 for recurrent glioma or metastatic brain cancer, it is initiating a Phase II multi-center North American clinical trial to include 66 patients with adult recurrent glioma. 131I-TM-601 is TransMolecular's anti-cancer therapeutic that incorporates a tumor targeting, biologically active and chemically synthesized 36 amino acid peptide derived from a naturally occurring protein found in scorpion venom that is conjugated with a medicinal radioisotope referred to as iodine 131.

The Phase I/II clinical trial included 18 recurrent high-grade glioma adult patients who were administered a single dose of 131I-TM-601 within 14 to 28 days after the recurrent brain tumors were surgically removed. Seventeen of the patients were diagnosed with glioblastoma multiforme, or GBM, one of the worst forms of glioma. Three sites participated in this multi-center trial. Median survival time for patients receiving 131I-TM-601 was 6.3 months compared to a median survival time of 4.6 months from published clinical studies of GBM with other treatments. Additionally, 11 out the 18 patients administered a single dose of 131I-TM-601 survived longer than six months, a notable improvement beyond the historical survival time for patients diagnosed with recurrent glioma and treated with conventional radiation and chemotherapy agents. Five glioma patients lived longer than one year and two patients out of 18 are still alive 21 months since surgery and treatment with a single dose of 131I-TM-601.

"The results from this Phase I/II clinical trial suggest that we have a well-tolerated, conveniently administered and promising anti-cancer agent against one of the deadliest forms of cancer -- recurrent GBM," stated Matthew A. Gonda, Ph.D., President and CEO. "We are encouraged by the favorable results from this Phase I/II clinical trial and after discussions with the U.S. Food and Drug Administration (FDA) we are preparing to enroll patients in a Phase II clinical trial that will be conducted at clinical sites throughout the United States and Canada."

According to the American Brain Tumor Association, it is estimated that 40,900 new cases of primary brain tumors will be diagnosed in 2004, of which approximately 19,000 plus cases will be diagnosed as malignant brain tumors, the rest are benign and curable. Moreover, it is estimated that during the year 2000, approximately 359,000 people in the United States were living after the diagnosis of a primary brain tumor. Unfortunately, a majority of people diagnosed and treated for malignant brain cancer experience recurrence of this deadly form of brain cancer and are faced with limited treatment options. Based on the unmet medical need in this patient population the FDA has granted this investigational drug Orphan Drug and Fast Track status.

ABOUT TRANSMOLECULAR, INC.

TransMolecular is a privately held biotechnology company committed to discovering, developing and commercializing novel and proprietary products to diagnose and treat diseases having inadequate pharmaceutical alternatives. The Company's cancer products are based on a 100% chemically synthesized 36 amino acid peptide derived from a naturally occurring protein found in scorpion venom. The Company's lead product, 131I-TM-601 for recurrent glioma, successfully completed a Phase I/II multi-center clinical trial and has started patient enrollment for a larger Phase II multi-center North American clinical trial in Q4 2004. The Company's second most advanced cancer product, TM-701 for treating peripheral solid tumors, is in preclinical development with an IND submission scheduled for 2005. The Company's corporate offices and research laboratories are located in Birmingham, Alabama. For more information, visit http://www.transmolecular.com .

SOURCE TransMolecular, Inc.
Web Site: http://www.transmolecular.com



Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740